(Press-News.org) Cancer researchers working on immunotherapies have made a big discovery: SLAMF6, a molecule on the surface of immune cells that prevents T cells from effectively attacking tumours – and, in mice, they've found a way to neutralize it.
Led by Université de Montréal medical professor Dr. André Veillette, director of the molecular oncology research unit at the UdeM-affiliated Montreal Clinical Research Institute (IRCM), the breakthrough is detailed in a study published in Nature.
An internal brake independent of tumor cells
In their lab, Veillette and his team demonstrated that, unlike other inhibitory molecules, SLAMF6 does not need to interact with tumour to weaken the immune response. It self-activates directly on the surface of T cells, sending a stop signal that:
weakens their attack capacity;
reduces the production of healthy, robust, long-lasting T cells;
and accelerates immune exhaustion, a state in which T cells become ineffective against cancer.
Current immunotherapies, such as PD1 or PDL1 inhibitors, “release the brakes” that tumours impose on the immune system. But a large number of patients either do not respond or eventually stop responding to these treatments.
To counter this effect, Veillette and his co-researchers developed new monoclonal antibodies that prevent SLAMF6 from interacting with itself. These antibodies have shown remarkable effects that include:
more activation of human T cells;
higher numbers of resilient immune cells;
fewer exhausted T-cells;
and strong anti-tumour responses in mice.
Outperform all other approaches
These new antibodies far outperform all currently available tools targeting SLAMF6, making them leading candidates for a new generation of anti-cancer immunotherapies, Veillette and his co-researchers believe.
The antibodies could offer an option for patients who no longer respond to PD1 or PDL1 treatments and could be used either alone or in combination with other immune-stimulating therapies, they say.
As a next step, Veillette’s team now wants to test these antibodies in early-phase clinical trials to evaluate their safety and efficacy in people with solid tumours or blood cancers.
“The discovery made by Dr. Veillette’s team opens the door to a new chapter in immunotherapy," said IRCM president and scientific director Dr. Jean-François Côté.
"By identifying an internal brake that had until now gone unrecognized and by developing antibodies capable of neutralizing it, our researchers are offering an innovative solution to the limitations of current treatments," he said.
"Rooted in a strategic vision to develop precision therapeutics, this breakthrough brings real hope to many patients and stands as a strong example of the impact of the translational research conducted at the IRCM.”
About this study
"SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer," by André Veillette et al., was published Feb. 11, 2026 in Nature. Funding was provided by the Canadian Institutes of Health Research (CIHR), the Terry Fox Research Institute, BioCanRx, Québec’s Ministry of Economy, Innovation and Energy, and the Canadian Foundation for Innovation.
END
Unraveling the mystery of why some cancer treatments stop working
2026-02-12
ELSE PRESS RELEASES FROM THIS DATE:
From polls to public policy: how artificial intelligence is distorting online research
2026-02-12
Artificial intelligence is increasingly able to simulate human behavior and answer online surveys and political polls, putting the reliability of survey-based research at risk. Consequences can be serious not only for science and research - online surveys are a cornerstone of modern social-science research - but also for policy and participation of people in democratic processes, as surveys are widely used in political polls. This is a worry expressed in a comment in Nature by three researchers ...
Climate policy must consider cross-border pollution “exchanges” to address inequality and achieve health benefits, research finds
2026-02-12
Ambitious climate action to improve global air quality could save up to 1.32 million lives per year by 2040, according to a new study.
The research, led by Cardiff University, shows how developing countries rely heavily on international cooperation to see these benefits, because much of their pollution originates outside their borders.
The first-of-its-kind study analysed these cross-border pollution “exchanges” for nearly every country – 168 in total.
Their findings, published in Nature Communications, reveal how a fragmented world, with little collaborative climate mitigation policymaking, would lead ...
What drives a mysterious sodium pump?
2026-02-12
Kyoto, Japan -- The enzyme Na⁺-NQR is a sodium pump that drives the respiration of many marine and pathogenic bacteria. Using redox reactions, the process of exchanging electrons between materials, it powers the transportation of sodium ions across the membrane, supporting the growth of the bacteria.
Yet there is a mystery behind this mechanism, as scientists have had trouble understanding exactly how the redox reactions are linked to sodium-pumping. In particular, the lack of structural information on the key intermediate states that form while the enzyme is operating has posed a major challenge; determining these structures is essential to understanding how the ...
Study reveals new cellular mechanisms that allow the most common chronic cardiac arrhythmia to persist in the heart
2026-02-12
Atrial fibrillation (AF), the most common chronic cardiac arrhythmia in clinical practice, is very challenging to treat once it becomes persistent, after which spontaneous return to normal rhythm becomes highly unlikely. A multidisciplinary study led by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and published in Circulation Research now provides a new perspective on why this arrhythmia can persist long-term, highlighting the key role of non-contractile cardiac cells.
AF has traditionally been viewed as a purely electrical disorder of cardiomyocytes—the heart’s contractile cells. However, the ...
Scientists discover new gatekeeper cell in the brain
2026-02-12
Ghent, 12 February 2026 – VIB and Ghent University researchers have identified and characterized a previously unknown cellular barrier in the brain, which sheds new light on how the brain is protected from the rest of the body. In a study published in Nature Neuroscience, the scientists also reveal a new pathway by which the immune system can impact the brain.
Prof. Roosmarijn Vandenbroucke (VIB–UGent Center for Inflammation Research): “These findings reveal how vulnerable and protectable the brain is, opening new perspectives for more targeted interventions in brain disorders.”
The ...
High blood pressure: trained laypeople improve healthcare in rural Africa
2026-02-12
In rural regions of Africa, high blood pressure often goes untreated because health centres are far away and there is a shortage of health professionals. A study in Lesotho shows that, with the help of a tablet app, villagers who have received training achieve better blood pressure control in their village community compared to normal treatment in healthcare facilities. The results provide the first robust data for an approach that could significantly improve access to blood pressure treatment in underserved regions. ...
Pitt research reveals protective key that may curb insulin-resistance and prevent diabetes
2026-02-12
Scientists at the University of Pittsburgh School of Medicine discovered a surprising new way the body can fight insulin resistance and diabetes – by boosting a special type of “good” immune cell in fat tissue.
Announced today in Nature Communications, the preclinical findings pave the path to develop a medication to treat and prevent type 2 diabetes, potentially replacing or supplementing GLP-1 weight maintenance drugs that lose effectiveness over time.
“One-third of our population is obese or overweight – over the next decade or so, ...
Queen Mary research results in changes to NHS guidelines
2026-02-12
Hundreds of people with advanced bladder cancer across the UK can now receive three rather than six chemotherapy cycles following research by Queen Mary University of London which has led to a change to NHS treatment guidelines. For people with the condition, this means fewer toxic side effects and a better quality of life during treatment.
Until recently, people with advanced bladder cancer routinely received between four to six cycles of intensive chemotherapy, followed by avelumab, a type of immunotherapy, as standard NHS care. ...
Sleep‑aligned fasting improves key heart and blood‑sugar markers
2026-02-12
Nighttime blood pressure dipped by 3.5%, heart rate dipped by 5% compared to controls
Given high adherence rate (nearly 90%), novel approach may be a more accessible non-pharmacological strategy for improving cardiometabolic health
‘It’s not only how much and what you eat, but also when you eat relative to sleep that is important’
CHICAGO --- A new Northwestern Medicine study has personalized overnight fasting by aligning it with individuals’ circadian sleep-wake rhythm — an important regulator of cardiovascular and metabolic function — without changing their caloric ...
Releasing pollack at depth could benefit their long-term survival, study suggests
2026-02-12
During 2026, new legislation – the result of an agreement between the UK Government and the European Union – is planned to come into force for recreational pollack fishing that limits catches to three fish per angler per day.
It will result in more fish being released after they are caught, but new research has suggested changing how that release happens could have a marked difference on the fisheries’ long-term sustainability.
Specifically, it suggests that releasing pollack closer to the depths they are normally caught could improve their chances of survival ...